mTOR Cancer Research Results

mTOR, mammalian target of rapamycin: Click to Expand ⟱
Source: HalifaxProj (inhibit)
Type:
mTOR (mechanistic target of rapamycin) is a central regulator of cell growth, proliferation, metabolism, and survival. It is a serine/threonine kinase that integrates signals from nutrients, growth factors, and cellular energy status.
mTOR promotes protein synthesis and cell growth by activating downstream targets such as S6 kinase and 4E-BP1. In cancer, this pathway can become hyperactivated, leading to uncontrolled cell proliferation.

mTor Inhibitors:
-rapamycin (Sirolimus): classic natural product mTOR inhibitor
-Curcumin
-Resveratrol
-Epigallocatechin Gallate (EGCG)
-Honokiol
Scientific Papers found: Click to Expand⟱
7086- GAR,    Garcinol: An emerging epigenetic modifier with versatile anticancer properties
- Review, Var, NA
AntiCan↑, TumCG↓, TumMeta↓, toxicity↓, Apoptosis↑, angioG↓, *BioAv↝, HATs↓, p300↓, CBP↓, PI3K↓, Akt↓, NF-kB↓, STAT↓, mTOR↓, DFF45↓, survivin↓, N-cadherin↓, Twist↓, MMP2↓, MMP3↓, MMP9↓, Mcl-1↓, EZH2↓, NOTCH↓, CXCR4↓, PGE2↓, VEGF↓, mPGES-1↓, CycB/CCNB1↓, CDK2↓, CDK4/6↓, iNOS↓, COX2↓, IL1↓, TNF-α↓, PARP↑, Bcl-2↓,
802- GAR,    Garcinol acts as an antineoplastic agent in human gastric cancer by inhibiting the PI3K/AKT signaling pathway
- in-vitro, GC, HGC27
TumCP↓, TumCI↓, Apoptosis↑, PI3K/Akt↓, Akt↓, p‑mTOR↓, cycD1/CCND1↓, MMP2↓, MMP9↓, BAX↑, Bcl-2↓,
7102- GEN,    Genistein: An Integrative Overview of Its Mode of Action, Pharmacological Properties, and Health Benefits
- Review, Var, NA
*antiOx↑, *Inflam↓, *Bacteria↓, *AntiViral↑, *Dose↝, *AntiDiabetic↑, angioG↑, Apoptosis↑, tumCV↓, MyD88↑, Beclin-1↑, LC3II↑, TLR4↑, TumAuto↑, mTOR↓, p62↓, TumCCA↑, TumCP↓, Akt↑, P53↑, DNMT3B↓, MEK↓, hTERT/TERT↓, VEGF↓, NF-kB↓, IAP1↓, MDR1↓, p‑Akt↓, eff↑, ChemoSen↑,
6569- Ger,    Geraniol inhibits cell growth and promotes caspase-dependent apoptosis in nasopharyngeal cancer C666-1 cells via inhibiting PI3K/Akt/mTOR signaling pathway
- in-vitro, NPC, C666-1
tumCV↓, MMP↓, Apoptosis↑, TBARS↑, GSH↓, SOD↓, BAX↑, Casp3↑, Casp9↑, PI3K↓, Akt↓, mTOR↓, DNAdam↑, ROS↑,
7201- GGB,    Ginkgolide B Inhibits EMT and Promotes Pyroptosis in Gastric Cancer via AKT/mTOR Pathway
- vitro+vivo, GC, AGS - in-vitro, GC, HGC27
TumCI↓, TumCMig↓, Apoptosis↑, Pyro↑, BAX↑, GSDMD↑, Bcl-2↓, TumCG↓, EMT↓, PCNA↓, N-cadherin↓, E-cadherin↑, PI3K↓, Akt↓, mTOR↓, Dose↝,
7277- GGB,    Ginkgolide B inhibits hydrogen peroxide-induced apoptosis and attenuates cytotoxicity via activating the PI3K/Akt/mTOR signaling pathway in H9c2 cells
- in-vitro, Nor, H9c2
*cardioP↑, *Bcl-2↑, *cl‑Casp3↓, *BAX↓, *PI3K↑, *Akt↑, *mTOR↑,
7288- GGB,    Anti-Angiogenic Properties of Ginsenoside Rg3 Epimers: In Vitro Assessment of Single and Combination Treatments
- in-vitro, BC, MDA-MB-231
TumCMig↓, TumCP↓, Apoptosis↑, VEGF↓, AQPs↓, Akt↓, p‑mTOR↓, eff↑,
7139- GI,    6-Shogaol Exhibits a Promoting Effect with Tax via Binding HSP60 in Non-Small-Cell Lung Cancer
- vitro+vivo, Lung, A549 - in-vitro, Melanoma, A375 - in-vitro, GBM, U251
HSP60/HSPD1↓, Apoptosis↑, TumCCA↑, mtDam↑, ERK↓, STAT3↓, PI3K↓, Akt↓, mTOR↓, ChemoSen↑, TumCG↓, TumCP↓, TumCG↓, Bcl-2↓, survivin↓, BAX↑, MMP↓, Dose↝,
7252- Gink,    STEAP2-associated modulation of PI3K/AKT/mTOR signaling contributes to ginkgetin-induced apoptosis in bladder cancer cells
- in-vitro, Bladder, 5637 - in-vitro, CRC, T24/HTB-9 - in-vitro, Bladder, J82 - in-vitro, Nor, SV-HUC-1
tumCV↓, selectivity↑, TumCMig↓, EMT↓, p‑PI3K↓, p‑Akt↓, p‑mTOR↓, STEAP3↓, Bax:Bcl2↑, cl‑Casp3↑,
7256- Gink,    Neuroprotective effect of ginkgetin in experimental cerebral ischemia/reperfusion via apoptosis inhibition and PI3K/Akt/mTOR signaling pathway activation
- in-vivo, Stroke, NA
*Stroke↓, *Apoptosis↓, *Casp3↓, *BAX↓, *Bcl-2↑, *p‑Akt↑, *p‑mTOR↑,
7285- Gins,    Ginsenoside Rg3 Alleviates Cisplatin Resistance of Gastric Cancer Cells Through Inhibiting SOX2 and the PI3K/Akt/mTOR Signaling Axis by Up-Regulating miR-429
- in-vitro, GC, AGS
ChemoSen↑, miR-429↑, SOX2↓, PI3K↓, Akt↓, mTOR↓,
3770- H2,    Role of Molecular Hydrogen in Ageing and Ageing-Related Diseases
- Review, AD, NA - Review, Park, NA
*antiOx↑, *NRF2↑, *HO-1↑, *Inflam↓, *neuroP↑, *cardioP↑, *other↓, *ROS↓, *NADPH↓, *Catalase↑, *GPx1↑, *NO↓, *mt-ROS↓, *SIRT3↑, *SIRT1↑, *TLR4↓, *mTOR↓, *cognitive↑, *Sepsis↓, *PTEN↓, *Akt↓, *NLRP3↓, *AntiAg↑, *IL6↓, *TNF-α↓, *IL1β↓, *MDA↓, *memory↑, *FOXO3↑, TumCG↓, *LDL↓,
3773- H2,    Role and mechanism of molecular hydrogen in the treatment of Parkinson’s diseases
- Review, Park, NA
*neuroP↑, *antiOx↑, *Inflam↓, *ROS↓, *NADPH↓, *NRF2↑, *BBB↑, *IL1β↓, *IL6↓, *TNF-α↓, *NF-kB↓, *NLRP3↓, *Sepsis↓, *p‑mTOR↓, *AMPK↑, *SIRT1↑, *HO-1↑,
2507- H2,    Hydrogen protects against chronic intermittent hypoxia induced renal dysfunction by promoting autophagy and alleviating apoptosis
- in-vivo, NA, NA
*RenoP↑, *ROS↓, *Apoptosis↓, *ER Stress↓, *CHOP/DDIT3↓, *Casp12↓, *GRP78/BiP↓, *LC3‑Ⅱ/LC3‑Ⅰ↑, *Beclin-1↑, *p62↓, *mTOR↓,
292- HCA,    Hydroxycitric Acid Inhibits Chronic Myelogenous Leukemia Growth through Activation of AMPK and mTOR Pathway
- in-vitro, AML, K562
ACLY↓, AMPK↑, mTOR↑, eIF2α↑, ATFs↑, TumCG↓,
2883- HNK,    Honokiol targets mitochondria to halt cancer progression and metastasis
- Review, Var, NA
ChemoSen↑, BBB↓, Ca+2↑, Cyt‑c↑, Casp3↑, chemoPv↑, OCR↓, mitResp↓, Apoptosis↑, RadioS↑, NF-kB↓, Akt↓, TNF-α↓, PGE2↓, VEGF↓, NO↝, COX2↓, RAS↓, EMT↓, Snail↓, N-cadherin↓, β-catenin/ZEB1↓, E-cadherin↑, ER Stress↑, p‑STAT3↓, EGFR↓, mTOR↓, mt-ROS↑, PI3K↓, Wnt↓,
2868- HNK,    Honokiol: A review of its pharmacological potential and therapeutic insights
- Review, Var, NA - Review, Sepsis, NA
*P-gp↓, *ROS↓, *TNF-α↓, *IL10↓, *IL6↓, eIF2α↑, CHOP/DDIT3↑, GRP78/BiP↑, BAX↑, cl‑Casp9↑, p‑PERK↑, ER Stress↑, Apoptosis↑, MMPs↓, cFLIP↓, CXCR4↓, Twist↓, HDAC↓, BMPs↑, p‑STAT3↓, mTOR↓, EGFR↓, NF-kB↓, Shh↓, VEGF↓, tumCV↓, TumCMig↓, TumCI↓, ERK↓, Akt↓, Bcl-2↓, Nestin↓, CD133↓, p‑cMET↑, RAS↑, chemoP↑, *NRF2↑, *NADPH↓, *p‑Rac1↓, *ROS↓, *IKKα↑, *NF-kB↓, *COX2↓, *PGE2↓, *Casp3↓, *hepatoP↑, *antiOx↑, *GSH↑, *Catalase↑, *RenoP↑, *ALP↓, *AST↓, *ALAT↓, *neuroP↑, *cardioP↑, *HO-1↑, *Inflam↓,
2885- HNK,    Honokiol: a novel natural agent for cancer prevention and therapy
NF-kB↓, STAT3↓, EGFR↓, mTOR↓, BioAv↝, Inflam↓, TumCP↓, angioG↓, TumCI↓, TumMeta↓, cSrc↓, JAK1↓, JAK2↓, ERK↓, Akt↓, PTEN↑, ChemoSen↑, chemoP↑, COX2↓, PGE2↓, TNF-α↓, IL1β↓, IL6↓, Casp3↑, Casp8↑, Casp9↑, cl‑PARP↑, DNAdam↑, Cyt‑c↑, RadioS↑, RAS↓, BBB↑, BioAv↓, Half-Life↝, Half-Life↝, toxicity↓,
2888- HNK,    Honokiol mediated inhibition of PI3K/mTOR pathway: A potential strategy to overcome immunoresistance in glioma, breast and prostate carcinoma without impacting T cell function
- in-vitro, Var, PC3 - in-vitro, BC, BT549
PI3K↓, mTOR↓, Inflam↓,
2891- HNK,    Honokiol, an Active Compound of Magnolia Plant, Inhibits Growth, and Progression of Cancers of Different Organs
- Review, Var, NA
AntiCan↑, Inflam↓, antiOx↑, selectivity↑, *toxicity↓, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, TumMeta↓, NADPH↓, MMP2↓, MMP9↓, p‑mTOR↓, EGFR↓, EMT↓, SIRT1↑, SIRT3↑, EZH2↓, Snail↓, Vim↓, N-cadherin↓, E-cadherin↑, COX2↓, NF-kB↓, *ROS↓, Ca+2↑, ROS↑,
2892- HNK,    Honokiol Induces Apoptosis, G1 Arrest, and Autophagy in KRAS Mutant Lung Cancer Cells
- in-vitro, Lung, A549 - in-vitro, Lung, H460 - in-vitro, Lung, H385 - in-vitro, Nor, BEAS-2B
TumCCA↑, Apoptosis↑, SIRT3↑, Hif1a↓, selectivity↑, p‑mTOR↓, p70S6↓,
2894- HNK,    Pharmacological features, health benefits and clinical implications of honokiol
- Review, Var, NA - Review, AD, NA
*BioAv↓, *neuroP↑, *BBB↑, *ROS↓, *Keap1↑, *NRF2↑, *Casp3↓, *SIRT3↑, *Rho↓, *ERK↓, *NF-kB↓, angioG↓, RAS↓, PI3K↓, Akt↓, mTOR↓, *memory↑, *Aβ↓, *PPARγ↑, *PGC-1α↑, NF-kB↓, Hif1a↓, VEGF↓, HO-1↓, FOXM1↓, p27↑, P21↑, CDK2↓, CDK4↓, CDK6↓, cycD1/CCND1↓, Twist↓, MMP2↓, Rho↑, ROCK1↑, TumCMig↓, cFLIP↓, BMPs↑, OCR↑, ECAR↓, *AntiAg↑, *cardioP↑, *antiOx↑, *ROS↓, P-gp↓,
4688- HNK,    Honokiol Suppresses Renal Cancer Cells’ Metastasis via Dual-Blocking Epithelial-Mesenchymal Transition and Cancer Stem Cell Properties through Modulating miR-141/ZEB2 Signaling
- vitro+vivo, RCC, A498
CSCs↓, EMT↓, TumCG↓, PI3K↓, Akt↓, mTOR↓, p‑Akt↓, PTEN↑, Wnt↓, β-catenin/ZEB1↓,
4640- HT,    The anti-cancer potential of hydroxytyrosol
- Review, Var, NA
selectivity↑, MMP↓, Cyt‑c↑, Casp9↑, Casp3↑, Bcl-2↓, BAX↑, MPT↑, Fas↑, PI3K↓, Akt↓, mTOR↓, Mcl-1↓, survivin↓, STAT3↓, EMT↓, TumCI↓, angioG↓, E-cadherin↑, N-cadherin↓, Snail↓, Twist↓, MMPs↓, MMP2↓, MMP9↓, VEGF↓, VEGFR2/KDR/Flk1↓, Hif1a↓, CSCs↓, CD44↓, Wnt↓, β-catenin/ZEB1↓,
4212- Hup,    Huperzine A Alleviates Oxidative Glutamate Toxicity in Hippocampal HT22 Cells via Activating BDNF/TrkB-Dependent PI3K/Akt/mTOR Signaling Pathway
- in-vitro, Nor, HT22
*ROS↓, *p‑Akt↓, *p‑mTOR↓, *p‑p70S6↓, *BDNF↑, *Apoptosis↓, *Casp3↓, *Bcl-2↑,
2180- itraC,    Repurposing Drugs in Oncology (ReDO)—itraconazole as an anti-cancer agent
- Review, Var, NA
Dose↝, toxicity↝, BioAv↑, Half-Life↝, BioAv↑, Dose↝, HH↓, TumAuto↑, Akt↓, mTOR↓, angioG↓, MDR1↓, TumCP↓, eff↑,
2179- itraC,    Repurposing itraconazole for the treatment of cancer
- Review, Var, NA
HH↓, angioG↓, TumCCA↑, MDR1↓, P-gp↓, mTOR↓, VEGF↓, Smo↓, Gli1↓, OS↑, PSA↓,
1168- IVM,  SRF,    Ivermectin synergizes sorafenib in hepatocellular carcinoma via targeting multiple oncogenic pathways
- in-vitro, HCC, NA
TumMeta↓, mTOR↓, EMT↓, CSCsMark↓, STAT3↓,
1918- JG,    ROS -mediated p53 activation by juglone enhances apoptosis and autophagy in vivo and in vitro
- in-vitro, Liver, HepG2 - in-vivo, NA, NA
TumCG↓, TumCP↓, Apoptosis↑, TumAuto↑, AMPK↑, mTOR↑, P53↑, H2O2↑, ROS↑, toxicity↝, p62↓, DR5↑, Casp8↑, PARP↑, cl‑Casp3↑,
5117- JG,    https://pubmed.ncbi.nlm.nih.gov/31283929/
- vitro+vivo, Liver, NA
TumCG↓, TumCP↓, Apoptosis↑, TumAuto↑, AMPK↑, mTOR↑, P53↑, H2O2↑, ROS↑,
862- Lae,    Molecular mechanism of amygdalin action in vitro: review of the latest research
- Review, NA, NA
BAX↑, Casp3↑, Bcl-2↓, Akt↓, mTOR↓, p19↑, TumCCA↑, other↓,
4293- LT,    Regulatory Role of NF-κB on HDAC2 and Tau Hyperphosphorylation in Diabetic Encephalopathy and the Therapeutic Potential of Luteolin
- in-vivo, Diabetic, NA
*Inflam↓, *antiOx↑, *neuroP↑, *cognitive↑, *p‑mTOR↓, *p‑NF-kB↓, *HDAC2↓, *BDNF↑, *other↓, *p‑tau↓,
2919- LT,    Luteolin as a potential therapeutic candidate for lung cancer: Emerging preclinical evidence
- Review, Var, NA
RadioS↑, ChemoSen↑, chemoP↑, *lipid-P↓, *Catalase↑, *SOD↑, *GPx↑, *GSTs↑, *GSH↑, *TNF-α↓, *IL1β↓, *Casp3↓, *IL10↑, NRF2↓, HO-1↓, NQO1↓, GSH↓, MET↓, p‑MET↓, p‑Akt↓, HGF/c-Met↓, NF-kB↓, Bcl-2↓, SOD2↓, Casp8↑, Casp3↑, PARP↑, MAPK↓, NLRP3↓, ASC↓, Casp1↓, IL6↓, IKKα↓, p‑p65↓, p‑p38↑, MMP2↓, ICAM-1↓, EGFR↑, p‑PI3K↓, E-cadherin↓, ZO-1↑, N-cadherin↓, CLDN1↓, β-catenin/ZEB1↓, Snail↓, Vim↑, ITGB1↓, FAK↓, p‑Src↓, Rac1↓, Cdc42↓, Rho↓, PCNA↓, Tyro3↓, AXL↓, CEA↓, NSE↓, SOD↓, Catalase↓, GPx↓, GSR↓, GSTs↓, GSH↓, VitE↓, VitC↓, CYP1A1↓, cFos↑, AR↓, AIF↑, p‑STAT6↓, p‑MDM2↓, NOTCH1↓, VEGF↓, H3↓, H4↓, HDAC↓, SIRT1↓, ROS↑, DR5↑, Cyt‑c↑, p‑JNK↑, PTEN↓, mTOR↓, CD34↓, FasL↑, Fas↑, XIAP↓, p‑eIF2α↑, CHOP/DDIT3↑, LC3II↑, PD-1↓, STAT3↓, IL2↑, EMT↓, cachexia↓, BioAv↑, *Half-Life↝, *eff↑,
4800- Lyco,    Recent insights on pharmacological potential of lycopene and its nanoformulations: an emerging paradigm towards improvement of human health
- Review, Var, NA
*antiOx↑, Keap1↝, NF-kB↝, NRF2↝, PI3K↝, Akt↝, mTOR↝, *GutMicro↑,
4786- Lyco,    Anti-proliferative and apoptosis-inducing activity of lycopene against three subtypes of human breast cancer cell lines
- in-vitro, BC, MDA-MB-468 - in-vitro, BC, MCF7 - in-vitro, BC, SkBr3
TumCP↓, TumCCA↑, cl‑PARP↑, ERK↑, cycD1/CCND1↓, P21↓, p‑Akt↓, mTOR↓, BAX↑, AntiCan↑, Risk↓,
4791- Lyco,    Investigating into anti-cancer potential of lycopene: Molecular targets
- Review, Var, NA
*antiOx↑, TumCP↓, TumCCA↓, Apoptosis↑, TumCI↓, angioG↓, TumMeta↓, *Risk↓, cycD1/CCND1↓, CycD3↓, cycE/CCNE↓, CDK2↓, CDK4↓, Bcl-2↓, P21↑, p27↑, P53↑, BAX↑, selectivity↑, MMP↓, Cyt‑c↑, Wnt↓, eff↑, PPARγ↑, LDL↓, Akt↓, PI3K↓, mTOR↓, PDGF↓, NF-kB↓, eff↑,
3265- Lyco,    Lycopene inhibits pyroptosis of endothelial progenitor cells induced by ox-LDL through the AMPK/mTOR/NLRP3 pathway
- in-vitro, Nor, NA
*AMPK↑, *mTOR↓, *NLRP3↓, *Pyro↓,
3275- Lyco,    Multifaceted Effects of Lycopene: A Boulevard to the Multitarget-Based Treatment for Cancer
- Review, Var, NA
TumCCA↑, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, P21↑, P53↑, GSK‐3β↓, p27↓, Akt↓, mTOR↓, ROS↓, MMPs↓, TumCI↓, TumCMig↓, NF-kB↓, *iNOS↓, *COX2↓, lipid-P↓, GSH↑, NRF2↑,
1126- Lyco,    Lycopene Inhibits Epithelial–Mesenchymal Transition and Promotes Apoptosis in Oral Cancer via PI3K/AKT/m-TOR Signal Pathway
- vitro+vivo, Oral, NA
TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, EMT↓, PI3K↓, Akt↓, mTOR↓, E-cadherin↓, BAX↑, N-cadherin↓, p‑PI3K↓, p‑Akt↓, p‑mTOR↓, Bcl-2↓,
2540- M-Blu,    Alternative mitochondrial electron transfer for the treatment of neurodegenerative diseases and cancers: Methylene blue connects the dots
- Review, Var, NA - Review, AD, NA
*OCR↑, *Glycolysis↓, *GlucoseCon↑, neuroP↑, Warburg↓, mt-OXPHOS↑, TumCCA↑, TumCP↓, ROS⇅, *cognitive↑, *mTOR↓, *mt-antiOx↑, *memory↑, *BBB↑, *eff↝, *ECAR↓, eff↑, lactateProd↓, NADPH↓, OXPHOS↑, AMPK↑, selectivity↑,
972- MAG,    Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1α/VEGF signaling pathway in human bladder cancer cells
- vitro+vivo, Bladder, T24/HTB-9
angioG↓, VEGF↓, H2O2↓, Hif1a↓, VEGFR2/KDR/Flk1↓, Akt↓, mTOR↓, P70S6K↓, 4E-BP1↓, TumCG↓, CD31↓, CA↓,
4514- MAG,    Magnolol and its semi-synthetic derivatives: a comprehensive review of anti-cancer mechanisms, pharmacokinetics, and future therapeutic potential
- Review, Var, NA
AntiCan↑, TumCP↓, TumCCA↑, TumMeta↓, angioG↓, NF-kB↓, MAPK↓, PI3K↓, Akt↓, mTOR↓, BioAv↓, *antiOx↑, *Inflam↓, *AntiAg↑, ChemoSen↑, cycD1/CCND1↓, CycB/CCNB1↓, cycE/CCNE↓, CDK2↓, CDK4↓, p27↑, P21↑, P53↑, PTEN↓, XIAP↓, Mcl-1↓, Casp3↑, Casp9↑, MMP9↑,
4515- MAG,    Magnolol as a Potential Anticancer Agent: A Proposed Mechanistic Insight
- Review, Var, NA
AntiCan↑, TumCP↓, TumCCA↑, Apoptosis↑, TumCMig↑, angioG↓, PI3K↓, Akt↓, mTOR↓, MAPK↓, NF-kB↓,
4528- MAG,    Pharmacology, Toxicity, Bioavailability, and Formulation of Magnolol: An Update
- Review, Nor, NA
*Inflam↑, *cardioP↑, *angioG↓, *antiOx↑, *neuroP↑, *Bacteria↓, AntiTum↑, TumCG↓, TumCMig↓, TumCI↓, Apoptosis↑, E-cadherin↑, NF-kB↓, TumCCA↑, cycD1/CCND1↓, PCNA↓, Ki-67↓, MMP2↓, MMP7↓, MMP9↓, TumCG↓, Casp3↑, NF-kB↓, Akt↓, mTOR↓, LDH↓, Ca+2↑, eff↑, *toxicity↓, *BioAv↝, *PGE2↓, *TLR2↓, *TLR4↓, *MAPK↓, *PPARγ↓,
4535- MAG,  5-FU,    Magnolol and 5-fluorouracil synergy inhibition of metastasis of cervical cancer cells by targeting PI3K/AKT/mTOR and EMT pathways
- in-vitro, Cerv, NA
ChemoSen↑, TumCP↓, vinculin↓, TumCA↓, TumCMig↓, TumCI↓, p‑Akt↓, p‑PI3K↓, mTOR↓, E-cadherin↑, β-catenin/ZEB1↑, Snail↓, Slug↓,
2643- MCT,    Medium Chain Triglycerides enhances exercise endurance through the increased mitochondrial biogenesis and metabolism
- Review, Nor, NA
*Akt↑, *AMPK↓, *TGF-β↓, eff↑, *BioEnh↑, *ATP↑, *PGC-1α↑, *p‑mTOR↑, *SMAD3↓,
2377- MET,    Metformin Inhibits TGF-β1-Induced Epithelial-to-Mesenchymal Transition via PKM2 Relative-mTOR/p70s6k Signaling Pathway in Cervical Carcinoma Cells
- in-vitro, Cerv, HeLa - in-vitro, Cerv, SiHa
EMT↓, P70S6K↓, mTOR↓, PKM2↓, Warburg↓, AMPK↑,
2378- MET,    Metformin inhibits epithelial-mesenchymal transition of oral squamous cell carcinoma via the mTOR/HIF-1α/PKM2/STAT3 pathway
- in-vitro, SCC, CAL27 - in-vivo, NA, NA
TumCP↓, TumCMig↓, TumCI↓, EMT↓, mTOR↓, Hif1a↓, PKM2↓, STAT3↓, E-cadherin↑, Vim↓, Snail↓, STAT3↓,
2374- MET,    Metformin Induces Apoptosis and Downregulates Pyruvate Kinase M2 in Breast Cancer Cells Only When Grown in Nutrient-Poor Conditions
- in-vitro, BC, MCF7 - in-vitro, BC, SkBr3 - in-vitro, BC, MDA-MB-231
eff↑, Apoptosis↑, Glycolysis↓, PKM2↓, mTOR↓, PARP↓,
2386- MET,    Mechanisms of metformin inhibiting cancer invasion and migration
- Review, Var, NA
OS↑, AMPK↑, EMT↓, TGF-β↓, mTOR↓, P70S6K↓, PKM2↓, Hif1a↓, ChemoSen↑,

Showing Research Papers: 201 to 250 of 356
Prev Page 5 of 8 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 356

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

HSP60/HSPD1↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   Catalase↓, 1,   CYP1A1↓, 1,   GPx↓, 1,   GSH↓, 3,   GSH↑, 1,   GSR↓, 1,   GSTs↓, 1,   H2O2↓, 1,   H2O2↑, 2,   HO-1↓, 2,   Keap1↝, 1,   lipid-P↓, 1,   NQO1↓, 1,   NRF2↓, 1,   NRF2↑, 1,   NRF2↝, 1,   OXPHOS↑, 1,   mt-OXPHOS↑, 1,   ROS↓, 1,   ROS↑, 5,   ROS⇅, 1,   mt-ROS↑, 1,   SIRT3↑, 2,   SOD↓, 2,   SOD2↓, 1,   TBARS↑, 1,   VitC↓, 1,   VitE↓, 1,  

Metal & Cofactor Biology(tgid=2) ⓘ

STEAP3↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

AIF↑, 1,   MEK↓, 1,   mitResp↓, 1,   MMP↓, 4,   MPT↑, 1,   mtDam↑, 1,   OCR↓, 1,   OCR↑, 1,   XIAP↓, 2,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ACLY↓, 1,   AMPK↑, 6,   ECAR↓, 1,   Glycolysis↓, 1,   lactateProd↓, 1,   LDH↓, 1,   LDL↓, 1,   NADPH↓, 2,   PI3K/Akt↓, 1,   PKM2↓, 4,   PPARγ↑, 1,   SIRT1↓, 1,   SIRT1↑, 1,   Warburg↓, 2,  

Cell Death(tgid=5) ⓘ

Akt↓, 22,   Akt↑, 1,   Akt↝, 1,   p‑Akt↓, 7,   Apoptosis↑, 17,   BAX↑, 10,   Bax:Bcl2↑, 1,   Bcl-2↓, 10,   Casp1↓, 1,   Casp3↑, 8,   cl‑Casp3↑, 2,   Casp8↑, 3,   Casp9↑, 4,   cl‑Casp9↑, 1,   CBP↓, 1,   cFLIP↓, 2,   Cyt‑c↑, 5,   DR5↑, 2,   Fas↑, 2,   FasL↑, 1,   GSDMD↑, 1,   HGF/c-Met↓, 1,   hTERT/TERT↓, 1,   IAP1↓, 1,   iNOS↓, 1,   p‑JNK↑, 1,   MAPK↓, 3,   Mcl-1↓, 3,   p‑MDM2↓, 1,   p27↓, 1,   p27↑, 3,   p‑p38↑, 1,   Pyro↑, 1,   survivin↓, 3,  

Kinase & Signal Transduction(tgid=6) ⓘ

cSrc↓, 1,   p70S6↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

EZH2↓, 2,   H3↓, 1,   H4↓, 1,   HATs↓, 1,   other↓, 1,   tumCV↓, 4,  

Protein Folding & ER Stress(tgid=8) ⓘ

ATFs↑, 1,   CHOP/DDIT3↑, 2,   eIF2α↑, 2,   p‑eIF2α↑, 1,   ER Stress↑, 2,   GRP78/BiP↑, 1,   p‑PERK↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

Beclin-1↑, 1,   LC3II↑, 2,   p62↓, 2,   TumAuto↑, 4,  

DNA Damage & Repair(tgid=10) ⓘ

DFF45↓, 1,   DNAdam↑, 2,   DNMT3B↓, 1,   P53↑, 6,   PARP↓, 1,   PARP↑, 3,   cl‑PARP↑, 2,   PCNA↓, 3,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK2↓, 6,   CDK4↓, 5,   CycB/CCNB1↓, 2,   cycD1/CCND1↓, 8,   CycD3↓, 1,   cycE/CCNE↓, 4,   p19↑, 1,   P21↓, 1,   P21↑, 4,   TumCCA↓, 1,   TumCCA↑, 11,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

4E-BP1↓, 1,   CD133↓, 1,   CD34↓, 1,   CD44↓, 1,   cFos↑, 1,   p‑cMET↑, 1,   CSCs↓, 2,   CSCsMark↓, 1,   EMT↓, 12,   ERK↓, 3,   ERK↑, 1,   FOXM1↓, 1,   Gli1↓, 1,   GSK‐3β↓, 1,   HDAC↓, 2,   HH↓, 2,   miR-429↑, 1,   mTOR↓, 31,   mTOR↑, 3,   mTOR↝, 1,   p‑mTOR↓, 6,   Nestin↓, 1,   NOTCH↓, 1,   NOTCH1↓, 1,   p300↓, 1,   P70S6K↓, 3,   PI3K↓, 14,   PI3K↝, 1,   p‑PI3K↓, 4,   PTEN↓, 2,   PTEN↑, 2,   RAS↓, 3,   RAS↑, 1,   Shh↓, 1,   Smo↓, 1,   SOX2↓, 1,   p‑Src↓, 1,   STAT↓, 1,   STAT3↓, 7,   p‑STAT3↓, 2,   p‑STAT6↓, 1,   TumCG↓, 12,   Wnt↓, 4,  

Migration(tgid=13) ⓘ

AXL↓, 1,   CA↓, 1,   Ca+2↑, 3,   CD31↓, 1,   Cdc42↓, 1,   CDK4/6↓, 1,   CEA↓, 1,   CLDN1↓, 1,   E-cadherin↓, 2,   E-cadherin↑, 7,   FAK↓, 1,   ITGB1↓, 1,   Ki-67↓, 1,   MET↓, 1,   p‑MET↓, 1,   MMP2↓, 7,   MMP3↓, 1,   MMP7↓, 1,   MMP9↓, 5,   MMP9↑, 1,   MMPs↓, 3,   N-cadherin↓, 7,   PDGF↓, 1,   Rac1↓, 1,   Rho↓, 1,   Rho↑, 1,   ROCK1↑, 1,   Slug↓, 1,   Snail↓, 6,   TGF-β↓, 1,   TumCA↓, 1,   TumCI↓, 11,   TumCMig↓, 10,   TumCMig↑, 1,   TumCP↓, 16,   TumMeta↓, 6,   Twist↓, 4,   Tyro3↓, 1,   Vim↓, 2,   Vim↑, 1,   vinculin↓, 1,   ZO-1↑, 1,   β-catenin/ZEB1↓, 4,   β-catenin/ZEB1↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 10,   angioG↑, 1,   EGFR↓, 4,   EGFR↑, 1,   Hif1a↓, 6,   NO↝, 1,   VEGF↓, 10,   VEGFR2/KDR/Flk1↓, 2,  

Barriers & Transport(tgid=15) ⓘ

AQPs↓, 1,   BBB↓, 1,   BBB↑, 1,   P-gp↓, 2,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

ASC↓, 1,   COX2↓, 4,   CXCR4↓, 2,   ICAM-1↓, 1,   IKKα↓, 1,   IL1↓, 1,   IL1β↓, 1,   IL2↑, 1,   IL6↓, 2,   Inflam↓, 3,   JAK1↓, 1,   JAK2↓, 1,   mPGES-1↓, 1,   MyD88↑, 1,   NF-kB↓, 14,   NF-kB↝, 1,   p‑p65↓, 1,   PD-1↓, 1,   PGE2↓, 3,   PSA↓, 1,   TLR4↑, 1,   TNF-α↓, 3,  

Protein Aggregation(tgid=19) ⓘ

NLRP3↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AR↓, 1,   CDK6↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 2,   BioAv↑, 3,   BioAv↝, 1,   ChemoSen↑, 9,   Dose↝, 4,   eff↑, 9,   Half-Life↝, 3,   MDR1↓, 3,   RadioS↑, 3,   selectivity↑, 6,  

Clinical Biomarkers(tgid=22) ⓘ

AR↓, 1,   BMPs↑, 2,   CEA↓, 1,   EGFR↓, 4,   EGFR↑, 1,   EZH2↓, 2,   FOXM1↓, 1,   hTERT/TERT↓, 1,   IL6↓, 2,   Ki-67↓, 1,   LDH↓, 1,   NSE↓, 1,   PSA↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 5,   AntiTum↑, 1,   cachexia↓, 1,   chemoP↑, 3,   chemoPv↑, 1,   neuroP↑, 1,   OS↑, 2,   Risk↓, 1,   toxicity↓, 2,   toxicity↝, 2,  
Total Targets: 283

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

Stroke↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 10,   mt-antiOx↑, 1,   Catalase↑, 3,   GPx↑, 1,   GPx1↑, 1,   GSH↑, 2,   GSTs↑, 1,   HO-1↑, 3,   Keap1↑, 1,   lipid-P↓, 1,   MDA↓, 1,   NRF2↑, 4,   ROS↓, 9,   mt-ROS↓, 1,   SIRT3↑, 2,   SOD↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ATP↑, 1,   OCR↑, 1,   PGC-1α↑, 2,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT↓, 1,   AMPK↓, 1,   AMPK↑, 2,   ECAR↓, 1,   GlucoseCon↑, 1,   Glycolysis↓, 1,   LDL↓, 1,   NADPH↓, 3,   PPARγ↓, 1,   PPARγ↑, 1,   SIRT1↑, 2,  

Cell Death(tgid=5) ⓘ

Akt↓, 1,   Akt↑, 2,   p‑Akt↓, 1,   p‑Akt↑, 1,   Apoptosis↓, 3,   BAX↓, 2,   Bcl-2↑, 3,   Casp12↓, 1,   Casp3↓, 5,   cl‑Casp3↓, 1,   iNOS↓, 1,   MAPK↓, 1,   Pyro↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

p‑p70S6↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↓, 2,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↓, 1,   ER Stress↓, 1,   GRP78/BiP↓, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

Beclin-1↑, 1,   LC3‑Ⅱ/LC3‑Ⅰ↑, 1,   p62↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ERK↓, 1,   FOXO3↑, 1,   HDAC2↓, 1,   mTOR↓, 4,   mTOR↑, 1,   p‑mTOR↓, 3,   p‑mTOR↑, 2,   PI3K↑, 1,   PTEN↓, 1,  

Migration(tgid=13) ⓘ

AntiAg↑, 3,   p‑Rac1↓, 1,   Rho↓, 1,   SMAD3↓, 1,   TGF-β↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,   NO↓, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 3,   P-gp↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2↓, 2,   IKKα↑, 1,   IL10↓, 1,   IL10↑, 1,   IL1β↓, 3,   IL6↓, 3,   Inflam↓, 6,   Inflam↑, 1,   NF-kB↓, 3,   p‑NF-kB↓, 1,   PGE2↓, 2,   TLR2↓, 1,   TLR4↓, 2,   TNF-α↓, 4,  

Synaptic & Neurotransmission(tgid=18) ⓘ

BDNF↑, 2,   p‑tau↓, 1,  

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 1,   NLRP3↓, 3,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   BioAv↝, 2,   BioEnh↑, 1,   Dose↝, 1,   eff↑, 1,   eff↝, 1,   Half-Life↝, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 1,   ALP↓, 1,   AST↓, 1,   GutMicro↑, 1,   IL6↓, 3,  

Functional Outcomes(tgid=23) ⓘ

AntiDiabetic↑, 1,   cardioP↑, 5,   cognitive↑, 3,   hepatoP↑, 1,   memory↑, 3,   neuroP↑, 6,   RenoP↑, 2,   Risk↓, 1,   toxicity↓, 2,  

Infection & Microbiome(tgid=24) ⓘ

AntiViral↑, 1,   Bacteria↓, 2,   Sepsis↓, 2,  
Total Targets: 112

Scientific Paper Hit Count for: mTOR, mammalian target of rapamycin
22 Curcumin
19 Fisetin
15 Quercetin
14 Berberine
13 Baicalein
9 Thymoquinone
9 Resveratrol
8 Apigenin (mainly Parsley)
8 Magnetic Fields
8 EGCG (Epigallocatechin Gallate)
8 Honokiol
8 Shikonin
7 Alpha-Lipoic-Acid
7 Artemisinin
6 diet FMD Fasting Mimicking Diet
6 Lycopene
6 Sulforaphane (mainly Broccoli)
6 Urolithin
5 Chemotherapy
5 Capsaicin
5 Magnolol
5 Metformin
5 Piperlongumine
5 Rosmarinic acid
5 Silymarin (Milk Thistle) silibinin
4 5-fluorouracil
4 Ashwagandha(Withaferin A)
4 Beta-Caryophyllene
4 Chlorogenic acid
4 Chrysin
4 Cinnamon
4 Citric Acid
4 Dichloroacetate
4 Gambogic Acid
4 Piperine
4 Pterostilbene
3 Coenzyme Q10
3 Astragalus
3 Cisplatin
3 brusatol
3 Carnosic acid
3 salinomycin
3 diet Short Term Fasting
3 Eugenol
3 Ginkgolide B
3 Hydrogen Gas
3 Magnetic Field Rotating
3 Naringin
2 1,8-Cineole
2 Auranofin
2 Silver-NanoParticles
2 Allicin (mainly Garlic)
2 Anethole/trans-Anethole
2 Betulinic acid
2 Brucea javanica
2 Boswellia (frankincense)
2 Carvacrol
2 Thymol-Thymus vulgaris
2 Propolis -bee glue
2 Hydroxycinnamic-acid
2 Calorie Restriction Mimetics
2 Ursolic acid
2 CUSP9
2 Deguelin
2 Dandelion Root
2 Ellagic acid
2 Emodin
2 Ferulic acid
2 Formononetin
2 Garcinol
2 Ginkgetin
2 HydroxyTyrosol
2 itraconazole
2 Juglone
2 Luteolin
2 Niclosamide (Niclocide)
2 doxorubicin
2 Plumbagin
2 α-Santalol/Sandalwood oil
2 Vitamin D3
1 Andrographis
1 Fennel Oil/Foeniculum vulgare
1 2-DeoxyGlucose
1 Baicalin
1 Biochanin A
1 Bufalin/Huachansu
1 Butyrate
1 Trastuzumab
1 Celastrol
1 Centella asiatica / Gotu kola → asiaticoside
1 Cichoric acid / Chicoric acid
1 immunotherapy
1 Spermidine
1 Aspirin
1 Crocetin
1 Radiotherapy/Radiation
1 diet Methionine-Restricted Diet
1 flavonoids
1 Fucoidan
1 Genistein (soy isoflavone)
1 Geraniol
1 Ginger/6-Shogaol/Gingerol
1 Ginseng
1 HydroxyCitric Acid
1 Huperzine A/Huperzia serrata
1 Ivermectin
1 Sorafenib (brand name Nexavar)
1 Laetrile B17 Amygdalin
1 Methylene blue
1 MCToil
1 Nimbolide
1 Oleuropein
1 Oleocanthal
1 sericin
1 Phenethyl isothiocyanate
1 Parthenolide
1 Gold NanoParticles
1 Selenium
1 Selenium NanoParticles
1 acetazolamide
1 Selenite (Sodium)
1 Aflavin-3,3′-digallate
1 Vitamin C (Ascorbic Acid)
1 γ-Tocotrienol
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:209  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page